SCHEMBL1200342

SCHEMBL1200342

N#CN1CCCC1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6691380 0.84
SCHEMBL1055705 0.75
SCHEMBL4080897 0.72
SCHEMBL30441147 0.70
SCHEMBL5487565 0.70
SCHEMBL23942057 0.70
SCHEMBL8065247 0.70
SCHEMBL30749102 0.70
SCHEMBL30749070 0.70
SCHEMBL30748840 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060293297-A1 Cyanofluoropyrrolidine derviative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-12-28 US claimed
EP-1627870-A1 CYANOFLUOROPYRROLIDINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-02-22 EP claimed
EP-2250157-B1 NOVEL HETEROCYCLIC COMPOUNDS PANACEA BIOTEC LTD (IN) 2014-11-05 EP disclosed
US-20110026010-A1 Optical Coherence Tomographic Analysis WALKER DWIGHT SHEROD 2011-02-03 US disclosed
EP-2250157-A1 NOVEL HETEROCYCLIC COMPOUNDS Panacea Biotec Limited (IN) 2010-11-17 EP disclosed
EP-2178440-A1 OPTICAL COHERENCE TOMOGRAPHIC ANALYSIS Glaxosmithkline LLC (US) 2010-04-28 EP disclosed
WO-2009093269-A1 NOVEL HETEROCYCLIC COMPOUNDS PANACEA BIOTEC LIMITED (IN) 2009-07-30 WO disclosed
WO-2009021092-A1 OPTICAL COHERENCE TOMOGRAPHIC ANALYSIS SMITHKLINE BEECHAM CORPORATION (US) 2009-02-12 WO disclosed
US-7462641-B2 (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-12-09 US disclosed
EP-1654226-B1 (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF SMITHKLINE BEECHAM CORP (US) 2008-10-22 EP disclosed
US-20070066677-A1 (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof SMITHKLINE BEECHAM CORPORATION 2007-03-22 US disclosed
CN-1791575-A Cyanofluoropyrrolidine derivative. TAISHO PHARMACEUTICAL CO LTD (JP) 2006-06-21 CN disclosed
CN-1791575-A Cyanofluoropyrrolidine derivative. TAISHO PHARMACEUTICAL CO LTD (JP) 2006-06-21 CN disclosed
EP-1654226-A1 (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF SmithKline Beecham Corporation (US) 2006-05-10 EP disclosed
EP-1627870-A1 CYANOFLUOROPYRROLIDINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-02-22 EP disclosed
EP-1627870-A1 CYANOFLUOROPYRROLIDINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-02-22 EP disclosed
JP-2005272457-A PHARMACEUTICAL CONTAINING CYANOPYRROLIDINE DERIVATIVE AS ACTIVE INGREDIENT TAISHO PHARMACEUT CO LTD 2005-10-06 JP disclosed
WO-2005009956-A1 (2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL]-2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2005-02-03 WO disclosed
WO-2004101514-A1 CYANOFLUOROPYRROLIDINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-11-25 WO disclosed
WO-2004092128-A1 ANHYDROUS CRYSTALLINE FORMS OF (2S, 4S)-1-{(2R)-2-AMINO-3-‘4-METHOXYBENZYL)SULFONYL!-3-METHYLBUTANOYL}-4-FLUOROPYRROLINDINE-2-CARBONITRILE SMITHKLINE BEECHAM CORPORATION (US) 2004-10-28 WO disclosed